Crizotinib
CDH1 Gene Mutation
Royal Marsden NHS Foundation TrustSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the CDH1 Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT Royal Marsden NHS Foundation Trust | Phase 2 | B |
TAMOXIFEN European Institute of Oncology | Phase 2 | CCC |
Same molecule, other indications
Crizotinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →